Farxiga does have a generic version, which may be a more accessible option for some people
10.3389/fncel.2014.00320 Front
Presented for research literature review only al-Ghais SM et al
A SURMOUNT-1 post-hoc analysis of 2,542 women, published in Obesity in 2025, found perimenopausal women on tirzepatide lost 23% of body weight against 3% on placebo, almost identical to the premenopausal result
Key end points included: hospitalisation, heart failure (ICD-10-CM-I50), myocardial infarction (ICD-10-CM-I21), stroke and transient ischaemic attack (ICD-10-CM-I63, G45), development of diabetic microvascular complications (ICD-10-CM-E10.210.4) and all-cause mortality analysed 3 months to 5 years post drug initiation